我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

cTnI在PCI相关心肌梗死中的临床应用进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第3期
页码:
362-365
栏目:
综述
出版日期:
2016-01-05

文章信息/Info

Title:
Progress in clinical application of cTnI in percutaneous coronary intervention related myocardial infarction
作者:
邱 珺1; 吴 刚2
（1.内蒙古医科大学研究生学院，内蒙古 呼和浩特 010110；
2.呼伦贝尔市人民医院心内科，内蒙古 海拉尔 021008）
Author(s):
QIU Jun1;  WU Gang2
(1.Graduate School, Inner Mongolia Medical University, Hohhot 010110, Inner Mongolia Autonomous Region, China；
2.Department of Cardiology, Hulunbuir People's Hospital, Hailaer 021008, Inner Mongolia Autonomous Region, China)
关键词:
经皮冠状动脉介入术; 围手术期心肌梗死; 心肌肌钙蛋白I
Keywords:
percutaneous coronary intervention;  peri-procedural myocardial infarction;  cardiac troponin I
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
随着人口老龄化以及不健康生活方式的影响，冠心病(coronary heart disease,CHD)的发病率逐年升高。经皮冠状动脉介入(percutaneous coronary intervention，PCI)术已经成为CHD患者心肌血运重建治疗的主要方式之一，并被广泛应用于临床。然而PCI相关心肌梗死(MI)即围手术期MI（PMI）的发生率也逐年上升，已逐渐被临床医师所重视，并且成为当下冠脉介入治疗(CI)研究的热点。心肌肌钙蛋白I（cTnI）作为心肌损伤最敏感的生化标志物，其在PMI中的应用也逐渐被重视。本文就cTnI在PCI相关MI中的临床应用价值的历年研究结果进行综述。
Abstract:
Population aging and unhealthy lifestyle have increased the incidence of coronary heart disease (CHD). Percutaneous coronary intervention (PCI) has become one of the main revascularization treatments for CHD and is widely used clinically. However, the incidence of PCI-related myocardial infarction (PMI) has increased year by year and PMI has become a hot research spot of coronary intervention treatment. Cardiac troponin I (cTnI) is the most sensitive biochemical maker of myocardial injury and is more and more used in PMI treatment. This article reviews the results of recent clinical studies on cTnI in PMI treatment.

参考文献/References

[1]Thygesen K,Alpert JS,Jaff AS,et al.Third universal definition of myocardial infarction[J].Eur Heart J,2012,33 (20):2551-2567.
[2]李玉芹，李会强.肌钙蛋白I的检测方法及研究进展[J].哈尔滨医药,2013,33(3):231-232.
[3]葛均波，徐永健.内科学[M].北京:人民卫生出版社,2013:248.
[4]Keller T,Zeller T,Peetz D,et al.Sensitive troponin I assay in early diagnosis of acute myocardial infarction[J].N Engl I Med,2009,361(9):868-877.
[5]Wang TY,Peterson ED,Dai D,et al.Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric:a report from the National Cardiovascular Data Registry(NCDR)[J].J Am Coll Cardiol,2008,51(21):2068-2074.
[6]Prasad A,Herrmann J.Myocardial infarction due to percutaneous coronary intervention[J].N Engl J Med,2011,364(5):453-464.
[7]Cavallini C,Verdecchia P,Savonitto S,el al.Prognostic value of isolated troponin I elevation after percutaneous coronary intervention[J].Circ Cardiovasc Interv,2010,3(5):431-435.
[8]席 锐，顾 刚，陶 蓉.经皮冠状动脉介入治疗患者围手术期TnI升高的相关因素分析[J].诊断学理论与实践,2013,12(2):175-178.
[9]Li XL,Li JJ,Guo YL,et al.Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention[J].J Clin Lipidol,2014,8(4):423-432.
[10]赵 强，肖 强，李元民，等.急性冠脉综合征患者PCI术后cTnI的变化及其对心脏不良事件的预测价值[J].中国医学装备,2014,11(2):25-28.
[11]Asaumi Y,Noguchi T,Morita Y,et al.High-Intensity Plaques on Noncontrast T1-Weighted Imaging as a Predictor of Periprocedural Myocardial Injury[J].JACC Cardiovasc Imaging,2015,8(6):741-743.
[12]赖 力，沈晓丽，刘小晴，等.cTnI自身抗体对两种cTnI检测方法检测结果的影响[J]. 心血管康复医学杂志,2013,22(3):261-265.
[13]White HD.The prequel.Defining prognostically important criteria in the periprocedural PCI troponin saga[J].Circ Cardiovasc Interv,2012,5(2):142-145.
[14]Jaffe AS,Apple FS,Lindahl B,et al.Why all the struggle about CK-MB and PCI?[J].Eur Heart J,2012,33(9):1046-1048.
[15]Damman P,Wallentin L,Fox KA,et al.Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome:A collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 Trials(FIR)[J].Circulation,2012,125(4):568-576.
[16]Lansky AJ,Stone GW.Periprocedural myocardial infarction:prevalence, prognosis,and prevention[J].Circ Cardiovasc Interv,2010,3(6):602-610.
[17]Prasad A Jr,Rihal CS,Lennon RJ,et al.Significance of periprocedural myonecrosis on outcomes following percutaneous coronary intervention[J].Circ Cardiovasc Intervent,2008,1(1):10-19.

备注/Memo

备注/Memo:
收稿日期：2015-01-16.
通讯作者：吴刚，主任医师，主要从事心脏病的介入治疗及研究 Email：wugang921@sohu.com
作者简介：邱珺，硕士生 Email：864946797@qq.com
更新日期/Last Update: 2016-01-07